Tandem Diabetes Care logo
Tandem Diabetes Care TNDM
$ 21.95 2.59%

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Tandem Diabetes Care Income Statement 2011-2025 | TNDM

Annual Income Statement Tandem Diabetes Care

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.23 B 1.47 B 2.58 B 7.44 B 5.65 B 4.33 B 2.08 B 15.6 M 70.3 M 261 M 286 M 75.4 M - -

Shares

65.9 M 65.4 M 64.1 M 63 M 61 M 58.5 M 48.1 M 5.68 M 3.06 M 2.89 M 2.33 M 294 K - -

Historical Prices

33.9 22.5 40.2 118 92.7 76 43.5 2.78 23.5 90.1 123 258 - -

Net Income

755 K -30 M -94.6 M 15.6 M -34.4 M -24.8 M -123 M -73 M -83.4 M -72.4 M -79.5 M -63.1 M -33 M -25.5 M

Revenue

283 M 197 M 801 M 703 M 499 M 362 M 184 M 108 M 84.2 M 72.8 M 49.7 M 29 M 2.47 M -

Cost of Revenue

451 M 380 M 388 M 327 M 238 M 168 M 94 M 63.5 M 60.7 M 46.3 M 34.5 M 22.8 M 3.82 M -

Gross Profit

157 M 93.3 M 413 M 376 M 261 M 194 M 89.8 M 44.1 M 23.6 M 26.6 M 15.2 M 6.17 M -1.35 M -

Operating Income

-581 K -35.1 M -92.8 M 22.7 M -7.96 M -16.7 M -44.6 M -62.9 M -78.1 M -69 M -75.7 M -49.4 M -33 M -

Interest Expense

7.26 M 13 M -4 K -6.75 M -28.3 M -7.88 M -77.9 M -10.1 M -5.41 M -3.4 M -3.79 M -13.7 M 33 K -

EBITDA

16 M -19.3 M -78.5 M 36.5 M 2.49 M -10.6 M -38.8 M -56.1 M -72.6 M -64.2 M -71.3 M -46.3 M -31 M -22.9 M

Operating Expenses

158 M 128 M 506 M 354 M 268 M 211 M 134 M 107 M 102 M 95.6 M 90.9 M 55.6 M 31.7 M -

General and Administrative Expenses

390 M 353 M 336 M 262 M 205 M 166 M 105 M 86.4 M 82.8 M 78.6 M 75.1 M - - -

All numbers in USD currency

Quarterly Income Statement Tandem Diabetes Care

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

67.7 M 67 M 66.4 M 66.3 M 65.5 M 65 M 65.3 M 65.6 M 65.1 M 64.8 M 64.5 M 64.5 M 64.2 M 64.1 M 63.9 M 63.8 M 63.2 M 62.7 M 62.4 M 62.2 M 61.5 M 60.4 M 59.7 M 59.2 M 58.8 M 58.2 M 57.8 M 57.6 M 55.6 M 50.9 M 18 M 10.1 M 5.19 M 5 M 3.19 M 3.11 M 3.06 M 30.5 M 30.3 M 30.3 M 30 M 29.9 M 25.5 M 23.7 M 23.5 M 23.1 M 22.9 M 22.9 M 214 K 211 K 208 K - - - - - - - -

Net Income

-21.2 M -52.4 M -131 M - -23.3 M -30.8 M -42.7 M - -33 M -35.8 M -124 M - -49 M -15.1 M -14.7 M 10.8 M 5.79 M 4.01 M -5.04 M 17 M -9.41 M -27.1 M -14.9 M 2.65 M -2.9 M -1.51 M -23 M 3.69 M -34.2 M -59.4 M -32.7 M -11.4 M -16 M -21.8 M -23.8 M -14.8 M -29.8 M -18.3 M -20.5 M -12.1 M -19.6 M -19.5 M -21.2 M -18.5 M -19.9 M -19.2 M -22 M -23.6 M -13.1 M -15.3 M -11.2 M - - - - - - - -

Revenue

249 M 241 M 234 M - 244 M 222 M 192 M - 186 M 196 M 169 M - 205 M 200 M 176 M 210 M 180 M 172 M 141 M 168 M 124 M 109 M 97.9 M 108 M 94.7 M 93.3 M 66 M 76.2 M 46.3 M 34.1 M 27.3 M 40.3 M 27 M 21.3 M 19 M 28.9 M 12.3 M 23 M 20.1 M 29.1 M 15.7 M 15.7 M 12.3 M 17.9 M 13.5 M 10.3 M 8.06 M 10.2 M 7.78 M 5.53 M 5.46 M - - - - - - - -

Cost of Revenue

115 M 115 M 116 M - 119 M 109 M 97 M - 95.9 M 94.2 M 86.5 M - 100 M 98.3 M 84.8 M - 82.9 M 79.7 M 67.8 M - 58.3 M 54.8 M 47.7 M - 44 M 43.4 M 32.6 M - 24.5 M 19 M 15.9 M - 15.1 M 13.3 M 12.2 M - 13.9 M 14.8 M 13.1 M - 10.2 M 10.9 M 9.5 M - 9.12 M 6.81 M 7.2 M - 5.24 M 5.12 M 3.42 M - - - - - - - -

Gross Profit

134 M 126 M 118 M - 125 M 113 M 94.7 M - 89.8 M 102 M 82.9 M - 104 M 102 M 91.1 M 114 M 96.7 M 92.5 M 73.3 M 90.6 M 65.3 M 54.4 M 50.3 M 60.3 M 50.7 M 49.9 M 33.4 M 41.5 M 21.8 M 15.1 M 11.4 M 17.5 M 11.9 M 8 M 6.75 M 10.1 M -1.58 M 8.18 M 6.93 M 13.5 M 5.51 M 4.8 M 2.81 M 6.54 M 4.4 M 3.45 M 867 K 1.19 M 2.53 M 406 K 2.04 M - - - - - - - -

Operating Income

-22.9 M -51.8 M -121 M - -26.1 M -30.8 M -41.7 M - -31.5 M -38.8 M -128 M - -47.5 M -12.2 M -15.3 M 12.7 M 7.72 M 5.43 M -3.24 M 18.7 M -1.01 M -12 M -13.6 M 2.14 M -6 M -1.86 M -11 M 560 K -15.7 M -14 M -15.5 M -9.58 M -13.2 M -19 M -21.2 M -13.3 M -28.4 M -17.1 M -19.2 M -11.2 M -18.7 M -18.7 M -20.4 M -17.5 M -19 M -18.3 M -20.8 M -16.5 M -12.1 M -13.7 M -7.17 M - - - - - - - -

Interest Expense

-2.28 M -5.91 M -1.21 M - 3.48 M 1.03 M 2.15 M - 816 K 4.18 M 4.23 M - 144 K -711 K -1.1 M - -1.87 M -1.36 M -1.92 M - -8.36 M -17.1 M -1.2 M - 3.18 M 353 K -12 M - -18.5 M -45.4 M -17.2 M - -2.87 M -2.83 M -2.57 M - -1.4 M -1.27 M -1.25 M - -882 K -862 K -798 K - -893 K -879 K -1.12 M - -934 K -1.62 M -4 M - - - - - - - -

EBITDA

- - -117 M - - - -37.6 M - - - -124 M - -36.8 M -12.2 M -11.7 M 12.7 M 18 M 5.43 M 248 K 18.7 M 6.02 M -8 M -11.7 M 2.14 M -1.57 M 1.08 M -9.56 M 560 K -11.4 M -11.1 M -14 M -9.58 M -8.43 M -16 M -19.8 M -13.3 M -24.4 M -14.3 M -17.9 M -11.2 M -15.1 M -16.3 M -19.2 M -17.5 M -15.9 M -16.4 M -19.9 M -16.5 M -9.66 M -12 M -6.38 M - - - - - - - -

Operating Expenses

157 M 178 M 239 M - 151 M 144 M 136 M - 121 M 141 M 211 M - 152 M 114 M 106 M 101 M 89 M 87 M 76.5 M 71.9 M 66.3 M 66.4 M 63.8 M 58.1 M 56.7 M 51.8 M 44.4 M 41 M 37.5 M 29.1 M 26.9 M 27 M 25 M 27 M 28 M 23.4 M 26.8 M 25.2 M 26.2 M 24.7 M 24.2 M 23.5 M 23.2 M 24 M 23.4 M 21.8 M 21.7 M 17.7 M 14.7 M 14.1 M 9.21 M - - - - - - - -

General and Administrative Expenses

108 M 110 M 114 M - 99.6 M 94.2 M 90.1 M - 79.3 M 97.6 M 89.8 M - 84.1 M 80.6 M 73.3 M - 64.9 M 66.5 M 58.6 M - 50.2 M 50.4 M 49.7 M - 44.6 M 40.6 M 35 M - 29.5 M 22.6 M 20.9 M - 20.1 M 22.1 M 22.8 M - 20.7 M 21.1 M 22 M - 19.1 M 19.6 M 19.4 M - 18.9 M 18.1 M 18 M - 12 M 11.3 M 6.88 M - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Tandem Diabetes Care (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.82 -1.04 % $ 132 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 307.08 -0.33 % $ 8.66 B usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 45.69 1.24 % $ 6.81 K usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 128.67 2.55 % $ 224 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 91.95 -0.67 % $ 135 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.18 10.56 % $ 119 M franceFrance
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 9.58 -2.84 % $ 688 M israelIsrael
InMode Ltd. InMode Ltd.
INMD
$ 14.35 -1.1 % $ 1.14 B israelIsrael
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.99 7.52 % $ 16 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 96.99 0.79 % $ 1.23 B usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Align Technology Align Technology
ALGN
$ 163.04 -1.44 % $ 12.2 B usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 1.04 -2.06 % $ 107 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 12.5 -1.66 % $ 338 M usaUSA
FONAR Corporation FONAR Corporation
FONR
$ 14.9 0.99 % $ 97.7 M usaUSA
AxoGen AxoGen
AXGN
$ 30.0 -1.3 % $ 1.33 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 40.3 -1.29 % $ 1.24 B usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 63.28 0.84 % $ 3.43 B britainBritain
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 17.83 1.31 % $ 411 M usaUSA
Globus Medical Globus Medical
GMED
$ 86.73 0.05 % $ 11.8 B usaUSA
LENSAR LENSAR
LNSR
$ 11.51 -0.04 % $ 133 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 13.51 0.67 % $ 1.04 B usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 19.79 -0.85 % $ 2.83 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 3.07 -9.71 % $ 4.79 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 72.39 -0.17 % $ 2.04 B costa-ricaCosta-rica